Role of gap junction in ischemic preconditioning

To investigate the role of gap junction in ischemic preconditioning (IPC). Sprague-Dawley rats were subjected to a 30 min coronary artery occlusion followed by 4 h of reperfusion (I/R). Rats were divided into seven groups: I/R, IPC/R, IPC/R + 5-hydroxydecanoic acid (mitochondrial ATP sensitive potas...

Full description

Saved in:
Bibliographic Details
Published inZhōnghuá xīnxuèguănbìng zázhì Vol. 34; no. 8; p. 690
Main Authors Su, De-chun, Chang, Zhi-wen, Fan, Shu-ying
Format Journal Article
LanguageChinese
Published China 01.08.2006
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:To investigate the role of gap junction in ischemic preconditioning (IPC). Sprague-Dawley rats were subjected to a 30 min coronary artery occlusion followed by 4 h of reperfusion (I/R). Rats were divided into seven groups: I/R, IPC/R, IPC/R + 5-hydroxydecanoic acid (mitochondrial ATP sensitive potassium channel antagonist), I/R + diazoxide (mitochondrial ATP sensitive potassium channel agonist), I/R + 5-hydroxydecanoic acid + diazoxide, I/R + 18beta-glycyrrhetinic acid (gap junction blocker) and I/R + 18beta-glycyrrhetinic acid + 5-hydroxydecanoic acid. Hemodynamics and myocardial infarct size were measured and connexin43 phosphorylation and subcellular distribution were determined by quantitative immunoblotting and confocal immunofluorescence. Infarct size was reduced in IPC/R, I/R + diazoxide and I/R + 18beta-glycyrrhetinic acid group (13.34% +/- 7.87%, 11.02% +/- 2.24%, and 15.03% +/- 11.35%, respectively; P < 0.001 vs. I/R group: 45.81% +/- 7.91%). 5-hydroxydecanoic acid abolished the cardioprotective eff
ISSN:0253-3758